NX210c

N/A

Report date: 2024/05/24 17:00:46

NME

Base Information

Drug NameNX210c

Drug Alias NameSCO-Spondin-Derived Peptide NX210cH-L-tryphophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond)NX210NX 218

ClassificationSmall molecules > Synthetic peptide

Mechanisms of ActionGlutamate receptor ionotropic AMPA modulatorsGlutamate [NMDA] receptor modulatorsApoptosis inhibitors +[4]

TargetsGlutamate receptor ionotropic AMPAGlutamate [NMDA] receptor

Therapy Area/IndicationsAmyotrophic Lateral SclerosisAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsFrance

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAxoltis Pharma

China Registration ClassN/A

Develop Information

Active CompaniesAxoltis Pharma

Inactive CompaniesN/A

Active IndicationsAmyotrophic Lateral SclerosisAlzheimer Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A